These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 32660376

  • 21. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ.
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
    Lipton A.
    Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
    [Abstract] [Full Text] [Related]

  • 23. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
    Watkins KR, Rogers JE, Atkinson B.
    Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
    [Abstract] [Full Text] [Related]

  • 24. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW.
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Symptomatic Hypocalcemia Associated with Zoledronic Acid Treatment for Osteoporosis: A Case Report.
    Al Elq AH.
    Oman Med J; 2013 Mar; 28(2):e043. PubMed ID: 31435469
    [Abstract] [Full Text] [Related]

  • 28. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
    Zekri J, Farag K, Yousof O, Zabani Y, Mohamed W, Ahmed GA.
    J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
    Henry D, von Moos R, Body JJ, Rider A, De Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y.
    Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
    [Abstract] [Full Text] [Related]

  • 31. [A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient].
    Okagawa Y, Sato Y, Onuma H, Osuga T, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Kato J.
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):867-70. PubMed ID: 26197752
    [Abstract] [Full Text] [Related]

  • 32. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa.
    Tanvetyanon T, Choudhury AM.
    Ann Pharmacother; 2004 Mar; 38(3):418-21. PubMed ID: 14970365
    [Abstract] [Full Text] [Related]

  • 33. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
    Watthanasuntorn K, Abid H, Gnanajothy R.
    BMJ Case Rep; 2018 Dec 13; 11(1):. PubMed ID: 30567243
    [Abstract] [Full Text] [Related]

  • 34. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW, Sundar S.
    Clin Genitourin Cancer; 2012 Mar 13; 10(1):50-3. PubMed ID: 22245101
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
    Santini D, Galvano A, Pantano F, Incorvaia L, Rizzo S, Vincenzi B, Castellana L, Giuliana G, Guadagni F, Toia F, Tonini G, Russo A, Badalamenti G, Bazan V.
    Crit Rev Oncol Hematol; 2019 Oct 13; 142():68-75. PubMed ID: 31377434
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA.
    J Clin Endocrinol Metab; 2015 Nov 13; 100(11):4163-71. PubMed ID: 26308295
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.